Video
Study finds focal therapy a safe option for treating intermediate-risk prostate cancer
Author(s):
Video Player is loading.
In this video, Behfar Ehdaie, MD, MPH, discusses the background and findings of the study, “MRI-guided focused ultrasound (MRgFUS) focal therapy for intermediate-risk prostate cancer: final results of a phase IIb multicenter study,” presented at the 2021 American Urological Association annual meeting. Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
